Literature DB >> 17141334

Cannabinoid CB2 receptor: a new target for controlling neural cell survival?

Javier Fernández-Ruiz1, Julián Romero, Guillermo Velasco, Rosa M Tolón, José A Ramos, Manuel Guzmán.   

Abstract

Two types of cannabinoid receptor have been cloned and characterized. Whereas CB1 receptors are ubiquitously expressed in neurons of the CNS, CB2 receptors have been thought to be absent from the CNS. Recent data now question this notion and support the expression of CB2 receptors in microglial cells, astrocytes and even some neuron subpopulations. This discrete distribution makes CB2 receptors interesting targets for treating neurological disorders because CB2-selective agonists lack psychoactivity. Here, we review evidence supporting the idea that CB2 receptors are implicated in the control of fundamental neural cell processes, such as proliferation and survival, and that their pharmacological manipulation might be useful for both delaying the progression of neurodegenerative disorders and inhibiting the growth of glial tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17141334     DOI: 10.1016/j.tips.2006.11.001

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  134 in total

Review 1.  Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Authors:  Javier Fernández-Ruiz; Onintza Sagredo; M Ruth Pazos; Concepción García; Roger Pertwee; Raphael Mechoulam; José Martínez-Orgado
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 2.  Latest advances in novel cannabinoid CB(2) ligands for drug abuse and their therapeutic potential.

Authors:  Peng Yang; Lirong Wang; Xiang-Qun Xie
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

3.  Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide.

Authors:  Stefania Merighi; Stefania Gessi; Katia Varani; Carolina Simioni; Debora Fazzi; Prisco Mirandola; Pier Andrea Borea
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

4.  Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.

Authors:  Suneeta Tumati; Tally M Largent-Milnes; Attila Keresztes; Jiyang Ren; William R Roeske; Todd W Vanderah; Eva V Varga
Journal:  J Neuroimmunol       Date:  2012-01-30       Impact factor: 3.478

5.  CoMFA and CoMSIA analyses on 1,2,3,4-tetrahydropyrrolo[3,4-b]indole and benzimidazole derivatives as selective CB2 receptor agonists.

Authors:  Elena Cichero; Sara Cesarini; Luisa Mosti; Paola Fossa
Journal:  J Mol Model       Date:  2010-02-20       Impact factor: 1.810

6.  Cannabinoid receptors CB1 and CB2 form functional heteromers in brain.

Authors:  Lucía Callén; Estefanía Moreno; Pedro Barroso-Chinea; David Moreno-Delgado; Antoni Cortés; Josefa Mallol; Vicent Casadó; José Luis Lanciego; Rafael Franco; Carmen Lluis; Enric I Canela; Peter J McCormick
Journal:  J Biol Chem       Date:  2012-04-24       Impact factor: 5.157

Review 7.  Cannabinoids and neuroprotection in basal ganglia disorders.

Authors:  Onintza Sagredo; Moisés García-Arencibia; Eva de Lago; Simone Finetti; Alessandra Decio; Javier Fernández-Ruiz
Journal:  Mol Neurobiol       Date:  2007-06-23       Impact factor: 5.590

Review 8.  The complications of promiscuity: endocannabinoid action and metabolism.

Authors:  S P H Alexander; D A Kendall
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

Review 9.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

Review 10.  Alzheimer's disease; taking the edge off with cannabinoids?

Authors:  V A Campbell; A Gowran
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.